We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Integrating surgical oncology into cancer care across Europe can be challenging, but it plays a critical role in cancer care. It was a pleasure to talk to Professor Isabel Rubio, President-Elect of the European Societ of Surgical Oncology (ESSO), to discuss current projects and initiatives of the society for the coming year and the recent […]
touchONCOLOGY spoke to Professor Pamela Kearns (University of Birmingham, UK) to discuss the importance of SIOP Europe, and the power of bringing together experts, patients and parents from the continent as one voice with one objective. Questions Why is it important to have organizations like SIOP Europe? (00:21-02:09) Is there any message you would like […]
touchONCOLOGY spoke to Professor Pamela Kearns (University of Birmingham, UK) to discuss her experience as President of SIOP Europe during the COVID-19 pandemic, and the biggest achievements of the European paediatric oncology community during that time. Questions How would you describe your experience as the SIOP Europe President (2019–21) and how the COVID-19 pandemic influenced […]
We were delighted to speak with Dr. Ruth Perets (Rambam Health Care Campus, Haifa, Israel) about the efficacy and safety findings of the phase 1 study comparing vibostolimab (vibo) plus pembrolizumab (pembro) given sequentially to the coformulation of vibo/pembro in ovarian cancer naive to PD-1/PD-L1 inhibitors. The abstract ‘Safety and efficacy of vibostolimab (vibo) plus […]
It was a pleasure to talk with Prof. Nicolas Girard (Institut Curie; Versailles Saint Quentin University, Paris, France) to discuss the findings from his analysis of event-free survival in the CheckMate-816 trial, investigating neoadjuvant nivolumab plus chemotherapy for resectable (IB-IIIA) non-small cell lung cancer. The abstract ‘Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as […]
touchONCOLOGY were delighted to talk with Dr. Neal Shore (GenesisCare; Carolina Urologic Research Center, Myrtle Beach, SC, USA) to discuss the phase 3 study of pembrolizumab plus chemoradiotherapy in the treatment of muscle-invasive bladder cancer. The abstract ‘KEYNOTE-992: A randomized phase 3 trial of pembrolizumab versus placebo in patients with muscle-invasive bladder cancer receiving concurrent […]
It was a pleasure to speak with Dr Lynsey Drewett (University of Cambridge, Cambridge, UK) around the PARTNER study, investigating the efficacy and safety of the addition of olaparib to neoadjuvant platinum-based chemotherapy in the treatment of basal TNBC and/or gBRCA breast cancer. The abstract ‘PARTNER: Randomised, phase II/III trial to evaluate the safety and […]
touchONCOLOGY spoke to Prof Misako Nagasaka (University of California Irvine, Detroit, MI, USA) to discuss her presentation at the European Lung Cancer Congress 2022, providing the results of the TRUST-II study, a global phase II study for taletrectinib in ROS1 fusion positive lung cancer and other solid tumours. Questions What is taletrectinib […]
The CASPIAN study evaluated the efficacy and safety of durvalumab plus tremelimumab and platinum-etoposide extensive-stage SCLC. touchONCOLOGY spoke to Niels Reinmuth (Munich, Germany) to discuss the characteristics of long-term survivors in the CASPIAN study. Clinical Trial Identification: NCT03043872 Questions What did the CASPIAN study teach us about the efficacy and safety of […]
Get the latest clinical insights from touchONCOLOGY